Scalper1 News
Big pharma Merck affirmed Wednesday that it’ll present much-anticipated data from its hepatitis C program at next month’s American Association for the Study of Liver Diseases Liver Meeting, but investors will have to wait till the meeting itself to find out the actual data. Bristol-Myers Squibb (BMY) was more forthcoming, but its results failed to ignite the stock. Merck (MRK) said that it will present data from its phase-two C-Swift trial, which Scalper1 News
Scalper1 News